That is potentially another good CML drug in the pipeline.
Rob
--- "Cheryl-Anne Simoneau" <[EMAIL PROTECTED]> wrote:
From: "Cheryl-Anne Simoneau" <[EMAIL PROTECTED]>
Date: Thu, 5 Jan 2006 08:25:07 -0500
To: "Cheryl-Anne Simoneau" <[EMAIL PROTECTED]>
Subject: [CML] INNOVIVE Pharmaceuticals Licenses Potent Dual Bcr-Abl/Lyn Kinase Inhibitor; Initial Development Target is Chronic Myelogenous Leukemia
INNOVIVE Pharmaceuticals Licenses Potent Dual Bcr-Abl/Lyn Kinase Inhibitor; Initial Development Target is Chronic Myelogenous Leukemia
1/5/2006 6:58:00 AM EST
INNOVIVE Pharmaceuticals Inc., a biopharmaceutical company headquartered in Manhattan, announced today that it has licensed worldwide development rights for NS-187 in all countries except Japan, from Nippon Shinyaku Co. Ltd., a Kyoto-based pharmaceutical company. INNOVIVE will develop NS-187 for the treatment of chronic myelogenous leukemia (CML) and anticipates commencing Phase I trials this year.
NS-187 is an orally bioavailable, rationally designed, dual Bcr-Abl and Lyn kinase inhibitor. Bcr-Abl is commonly recognized as the primary molecular target in the treatment of CML. According to a study published in the journal Blood (Dec. 1, 2005), NS-187 is 25 to 55 times more potent than imatinib mesylate (Gleevec(TM)) in vitro, and at least 10 times as effective as imatinib mesylate in suppressing the growth of Bcr-Abl bearing tumors. NS-187 also demonstrated activity in 12 of 13 Gleevec-resistant cell lines.
In addition to its Bcr-Abl inhibitory properties, NS-187 was designed to inhibit Lyn kinase. Lyn kinase activity is upregulated in some CML patients when resistance to Gleevec has developed. Lyn kinase activation has also been documented in a variety of solid tumors, including prostate cancer.
"CML is becoming a chronic condition in which patients will need several different treatment options. I am very excited about NS-187 because of its potent inhibition of Bcr-Abl and its specificity for Lyn which could contribute to a unique efficacy and toxicity profile," said Hagop M. Kantarjian, M.D., chairman of the Department of Leukemia at the M.D. Anderson Cancer Center.
"We are pleased to add NS-187 to INNOVIVE's oncology pipeline. The compound shows great promise over existing treatments for CML," said Steven Kelly, president and chief executive officer, INNOVIVE Pharmaceuticals Inc.
"Nippon Shinyaku is confident that NS-187 will be professionally and responsibly developed by INNOVIVE. We look forward to the drug's progress so it can help the thousands of people worldwide diagnosed each year with CML," said Kazuto Hatsuyama, president, Nippon Shinyaku Co. Ltd.
About CML
Chronic myelogenous leukemia is a slow-growing form of leukemia, a cancer of the bone marrow and blood. It starts in the blood-forming cells of the bone marrow and can spread to a variety of organs. CML is capable of changing to acute leukemia, which is fast growing and can spread to any organ in the body. Approximately 4,300 people are diagnosed with CML each year in the United States, and 1,700 die each year from the disease. The current prevalence of CML in the United States is estimated at over 20,000. This figure is expected to grow significantly as the recent approval of Bcr-Abl inhibitors has increased survival by many years. The most common first line treatment of CML is imatinib mesylate. Even with this powerful new agent, imatinib mesylate resistant and refractory patients occur at a rate of 4-13% of the treated population per year.
About INNOVIVE Pharmaceuticals
INNOVIVE Pharmaceuticals Inc. is a privately held biopharmaceutical company headquartered in New York. The company's mission is to acquire, develop and commercialize novel therapeutics addressing significant unmet medical needs in the fields of oncology and hematology. INNOVIVE currently is developing INNO-105, a naturally occurring peptide that inhibits cell growth and division by interacting with OGFr, a unique receptor found on the nuclear membrane of a wide range of malignant cells. The company recently announced it had enrolled the first patients in a Phase I clinical trial of INNO-105 in adult patients with advanced solid malignancies. For additional information visit www.innovivepharma.com.
About Nippon Shinyaku Co. Ltd.
Nippon Shinyaku, based in Kyoto, Japan, was founded in 1919 and is an R&D-oriented pharmaceutical company specializing in the development, manufacture, and sale of ethical drugs for the treatment of urological, inflammatory and allergic diseases and hematological malignancies. Nippon Shinyaku currently employs about 1800 employees and the total revenue in fiscal 2005 is reported about US$500 million. For additional information, please visit www.nippon-shinyaku.co.jp.
Powered by NewOrleansEmail.Com http://neworleansemail.com
New! Sign up for local CML support group meetings in your local community at http://cml.meetup.com
Apply for Commercial Real Estate loans online and submit your deal to dozens of hungry lenders in just minutes. Loan programs for all types of business and commercial real estate. Apply anytime at http://realestatezoo.com
CML (Chronic Myelogenous Leukemia Support List)
---------------------------------
Part Of CMLHope.Com
An International Community Of CML Patients
For more information: http://cmlhope.com
Post Message: cml@yahoogroups.com
Subscribe: [EMAIL PROTECTED]
Unsubscribe: [EMAIL PROTECTED]
Change To No Mail/Web: [EMAIL PROTECTED]
Change To Digest: [EMAIL PROTECTED]
Change To Email: [EMAIL PROTECTED]
List Help: [EMAIL PROTECTED]
CML Group Web Site http://groups.yahoo.com/group/CML
YAHOO! GROUPS LINKS
- Visit your group "CML" on the web.
- To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]
- Your use of Yahoo! Groups is subject to the Yahoo! Terms of Service.
